Lupin receives approval for Penicillamine Tablets USP

Pharma major Lupin Limited (Lupin) announced that it has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depen® Tablets, 250 mg, of Mylan Specialty, L.P. The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.

Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson's disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP (RLD: Depen®) had an annual sales of approximately USD 4 million in the U.S. (IQVIA MAT September 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.891.8 as compared to the previous close of Rs. 899.45. The total number of shares traded during the day was 117513 in over 4673 trades.

The stock hit an intraday high of Rs. 914.4 and intraday low of 889.5. The net turnover during the day was Rs. 106290904.

Source : Equity Bulls

Keywords